Wegovy Injections (Ireland)

What is Wegovy 

Wegovy is a prescription weight-loss injection that contains semaglutide, a medication that helps regulate appetite and food intake. It is used alongside diet and physical activity to support weight loss in adults living with overweight or obesity under medical supervision. 

Who manufactures Wegovy in Ireland? 

Wegovy is manufactured by Novo Nordisk, a global pharmaceutical company specialising in diabetes and obesity treatments. The company developed semaglutide and produces Wegovy for international markets, including Ireland, under strict regulatory oversight. 

How does semaglutide work? 

Semaglutide works by mimicking a natural hormone that helps control appetite and digestion. It reduces hunger signals in the brain and slows the emptying of the stomach, helping people feel fuller for longer and naturally eat fewer calories. 

The medication belongs to a class of drugs known as GLP-1 receptor agonists, which influence several biological processes linked to hunger and metabolism.  

When semaglutide activates GLP-1 receptors, it helps regulate the signals between the gut and the brain that tell you when you are hungry or full. This can help reduce appetite and make it easier to eat less. 

The GLP-1 mechanism of action 

A mechanism of action describes how a medication works in the body to produce its effects. It explains the biological processes the treatment influences. 

GLP-1 (glucagon-like peptide-1) is a natural hormone released in the gut after eating that helps regulate appetite and blood sugar levels. Semaglutide works by mimicking this hormone and activating the same GLP-1 receptors involved in hunger, digestion, and glucose control. 

When GLP-1 receptors are activated, several effects occur: 

• The brain receives stronger “fullness” signals, helping reduce appetite 
• Stomach emptying slows, meaning food stays in the stomach for longer 
• Insulin release increases when blood sugar rises, supporting glucose regulation 
• Glucagon levels decrease, helping stabilise blood sugar levels 

How effective is Wegovy? 

Wegovy can lead to significant weight loss when used alongside diet and physical activity. Clinical trials show that many people can lose around 22% of their starting body weight over about 72 weeks when taking semaglutide with lifestyle support. 

Wegovy is one of the most effective prescription weight-loss medications currently available. Its effectiveness has been demonstrated in several large clinical trials, including the STEP trial programme, which studied semaglutide for long-term weight management. 

How much weight loss is possible? 

Wegovy can lead to significant weight loss when used alongside changes to diet and physical activity. In clinical studies, semaglutide has shown meaningful results for people living with overweight or obesity when combined with lifestyle support. 

In the STEP 1 trial, adults taking semaglutide 2.4mg alongside lifestyle changes lost an average of 14.9% of their body weight after 68 weeks, compared with 2.4% in the placebo group who received lifestyle advice alone.  

The STEP UP trial investigated semaglutide 7.2mg for adults with obesity. After 72 weeks, participants taking 7.2mg lost an average of 18.7% of their starting body weight, compared with 3.9% in the placebo group. During this trial, patients lost up to 21% of their weight. 

These results show that semaglutide can lead to substantial weight loss for many people when used as part of a structured weight management plan that includes dietary changes and regular physical activity. 

It’s also important to remember that not everyone will experience the same results or timeline for their weight loss. Results can vary depending on several factors, including: 

• starting body weight 
• consistency with weekly injections 
• dietary habits 
• physical activity levels 
• duration of treatment 

How long does it take to start working? 

Wegovy starts working quickly and usually begins affecting appetite within the first few weeks, but noticeable weight loss typically develops gradually over several months. It is designed to support steady, long-term weight reduction rather than rapid short-term results. 

Treatment begins with a low starting dose of 0.25mg, which is gradually increased over several weeks. This slow dose escalation helps the body adjust to the medication and reduces the risk of side effects such as nausea. 

During the first few weeks, many people notice: 

• reduced appetite 
• feeling full sooner when eating 
• less frequent food cravings 

Weight loss usually becomes more noticeable after the dose increases and treatment continues for several months. Clinical trials assessing Wegovy’s effectiveness typically measure outcomes after 68 weeks of treatment, reflecting its role as a long-term therapy. 

Will I regain weight if I stop taking Wegovy? 

Research suggests that some people may regain weight after stopping Wegovy. In follow-up analyses of the STEP clinical trials, participants who discontinued semaglutide regained around two-thirds of the weight they had lost within about 1 year. 

This happens because the medication’s effects on appetite, fullness and stomach emptying gradually wear off once treatment stops. 

For this reason, Wegovy is typically used as part of a long-term weight management approach, rather than a short-term diet solution. Maintaining habits such as balanced nutrition, regular physical activity, and behavioural support can help people maintain their results after treatment. 

How myBMI Ireland works 

myBMI provides medically supervised access to Wegovy in Ireland through an online consultation and prescription service. If you are eligible for treatment, we can issue a prescription for Wegovy, which can be provided by our partner pharmacy or a pharmacy of your choice. 

The service is designed to combine medical oversight with structured weight management support, helping people access evidence-based treatment responsibly. myBMI focuses on providing a complete care pathway that includes assessment, education, and continued follow-up. 

Ongoing care and support 

myBMI provides ongoing clinical support throughout your Wegovy treatment to help ensure safe, effective, and sustainable weight loss. Regular check-ins and guidance help patients manage side effects, stay consistent with treatment, and maintain healthy lifestyle changes. 

Weight management is a long-term process, and medication works best when supported by continued care. During treatment, patients can receive clinical guidance, educational resources, and monitoring to ensure progress remains safe and effective. 

What’s included in our service? 

The myBMI service includes consultation, prescription assessment, and ongoing clinical support to help you use Wegovy safely and effectively. If you are eligible, we can issue a prescription and guide you through the treatment process. 

What’s included: 

Your consultation 

You will complete an online consultation covering your health history, weight management goals, and current medications. This information helps the prescriber determine whether Wegovy is safe and appropriate for you. 

Your digital prescription (if eligible) 

If the prescriber determines that treatment is suitable, they can issue a digital prescription for Wegovy, which allows the medication to be dispensed through a partner pharmacy. 

Helpful resources to manage diet and physical activity 

Patients receive practical guidance and educational resources to support lifestyle changes that enhance treatment results, including nutrition advice and physical activity recommendations. 

Ongoing patient care 

myBMI provides continued clinical oversight throughout treatment, helping monitor progress and ensure the medication remains suitable as weight loss develops. 

Side effects advice and treatment 

Patients receive information about common side effects such as nausea, bloating, tiredness, constipation, and diarrhoea, along with guidance on when to seek medical advice. We also provide free side effect treatments to support our patients by making their weight loss as comfortable as possible.  

“Wegovy can be a powerful tool for weight management when used as part of a structured medical programme. By targeting appetite and metabolic regulation, the treatment helps many patients reduce food intake and achieve meaningful weight loss. With appropriate monitoring and lifestyle support, it can form part of a safe and sustainable long-term weight management plan.” - myBMI prescribing clinician.

Wegovy doses and titration 

Wegovy treatment starts at a low dose and gradually increases over several weeks. This process, called dose titration, allows the body to adjust to treatment while reducing the risk of side effects like nausea or digestive discomfort. 

What are the doses of Wegovy? 

Wegovy is available in 5 dose strengths that are introduced gradually during treatment. The dose starts low and increases over time so the body can adjust to the medication and reduce the likelihood of digestive side effects. 

The available doses of Wegovy are: 

• 0.25mg 
• 0.5mg 
• 1mg 
• 1.7mg 
• 2.4mg 
• 7.2mg 

Wegovy dosage and titration chart 

What is the most effective dose of Wegovy?

For most patients, the most effective dose of Wegovy is 7.2mg once weekly. This is the highest maintenance dose used in clinical trials and prescribing guidance for long-term weight management. 

Clinical trials studying semaglutide for weight management recently evaluated the 7.2mg weekly dose, which was shown to be the most effective dose of Wegovy, leading to up to 21% weight loss. 

Wegovy 2.4mg

Wegovy 2.4mg is the full maintenance dose used for long-term weight management. This dose is taken once per week after completing the gradual dose increasing schedule. 

Most clinical studies evaluating Wegovy for weight loss used the 2.4mg weekly dose, which is why it is considered the target treatment level for many patients. 

At this dose, the medication produces its full therapeutic effects on appetite regulation and calorie intake.

Wegovy 7.2mg

Wegovy 7.2mg is a newer, higher dose of semaglutide developed for weight management. It may be considered for people who have already gone through the standard dosing schedule and may benefit from a higher dose under clinical supervision. 

Clinical research has shown that 7.2mg can lead to greater average weight loss compared with the 2.4mg dose in some patients. In the STEP UP trial, adults living with obesity who received semaglutide 7.2mg achieved an average weight loss of 18.7% over 72 weeks, compared with 15.6% with 2.4mg and 3.9% with placebo.  

As with other semaglutide doses, 7.2mg is taken once weekly and used alongside lifestyle support such as improved nutrition and regular physical activity. The most suitable dose will always be determined by a clinician based on how well the treatment is tolerated and how the body responds.

Why do you have to increase your Wegovy dose

Your Wegovy dose is increased gradually so your body can adjust to the medication. 

Starting on a low dose helps reduce common side effects such as nausea, vomiting, or stomach upset. Over time, the dose is slowly increased until you reach the maintenance dose that provides the full effect on appetite and weight management. 

This step-by-step approach, called dose titration, helps make treatment easier to tolerate while still allowing the medication to work effectively. 

Wegovy vs other weight loss medications

Wegovy is one of several prescription medications used to support weight loss. Other treatments like Mounjaro and Ozempic also affect appetite and metabolism, but they work slightly differently and can be prescribed for different purposes. 

These medications belong to a group of drugs that influence hormones involved in appetite and blood sugar regulation. While they share similarities, they vary in active ingredients, clinical indications, dosing schedules, and weight-loss outcomes. 

Wegovy vs Mounjaro

Wegovy and Mounjaro are both weekly injections used for weight management, but they contain different active ingredients and work through slightly different hormone pathways. Both medications can lead to substantial weight loss when combined with lifestyle changes.  

Semaglutide works by activating GLP-1 receptors, which regulate appetite and digestion. Tirzepatide activates both GLP-1 and GIP receptors, which may influence metabolism through additional hormonal pathways. Due to this, Mounjaro is often called a ‘dual action’ treatment. 

Clinical studies suggest both medications can produce significant weight loss when used alongside lifestyle support. The most suitable option depends on individual health factors, medical history, and clinician guidance.

Switching from Mounjaro to Wegovy

Some patients may switch from Mounjaro to Wegovy if their clinician determines it is appropriate. Switching medications may be considered if a patient experiences side effects, supply issues, or if a different treatment option is better suited to their needs. 

Because both medications influence appetite hormones, clinicians usually recommend careful timing and dose planning when switching treatments. This may involve: 

• waiting until the next scheduled injection week 
• starting Wegovy at a lower introductory dose 

A healthcare professional will normally guide the transition to ensure treatment remains safe and effective

Wegovy vs Ozempic

Wegovy and Ozempic contain the same active ingredient, semaglutide, but they are approved for different uses and are prescribed at different doses. Wegovy is licensed for weight management, while Ozempic is primarily prescribed for type 2 diabetes. 

Although both medications affect appetite and digestion, Wegovy is formulated and dosed specifically for obesity treatment. The higher maintenance dose used with Wegovy allows for stronger weight-loss effects compared with the doses commonly used for diabetes management.

Who is eligible for Wegovy in Ireland

Wegovy may be prescribed to adults living with obesity or overweight when lifestyle changes alone have not been sufficient for weight loss. Eligibility is usually based on body mass index (BMI) and the presence of weight-related health conditions. 

Clinical guidance generally recommends Wegovy for adults who have: 

• a BMI of 30 or above (obesity) 
• a BMI of 27 or above with weight-related health conditions, such as high blood pressure, type 2 diabetes, or sleep apnoea 

A clinician must review your medical history, medications, and overall health before prescribing the treatment. This helps ensure that Wegovy is safe and appropriate for you. 

Is it suitable for any age?

Wegovy is generally prescribed for adults aged 18 and over. It is not typically recommended for anyone younger, and eligibility is determined by a healthcare professional after reviewing medical history and health risks. 

Clinical trials for semaglutide in weight management have mainly focused on adults with obesity or overweight. Because of this, prescribing decisions are based on adult safety and effectiveness data. 

Can you take Wegovy while pregnant or breastfeeding?

Wegovy should not be used during pregnancy and is generally not recommended while breastfeeding. If you are pregnant, planning to become pregnant, or breastfeeding, you should speak to a healthcare professional before starting treatment. 

Weight-loss medications are not recommended during pregnancy because intentional weight loss may harm fetal development. For this reason, Wegovy should be stopped if pregnancy occurs. 

Does Wegovy affect contraception?

Wegovy does not directly reduce the effectiveness of most contraception. However, gastrointestinal side effects such as vomiting or severe diarrhoea may temporarily affect the absorption of oral contraceptive pills. 

If vomiting occurs soon after taking an oral contraceptive pill, the pill may not be fully absorbed. In this situation, additional contraception may be recommended. 

Who shouldn’t take Wegovy?

Wegovy is not suitable for everyone. Certain medical conditions or risk factors may mean the medication should not be prescribed. A clinician will assess safety during your consultation. 

Wegovy may not be appropriate for people who: 

• are pregnant or planning a pregnancy 
• have a history of severe allergic reaction to semaglutide 
• have certain thyroid tumours or a family history of medullary thyroid cancer 
• have a history of pancreatitis 
• have severe gastrointestinal disease 

Patients should also inform their clinician if they: 

• take medications that affect blood sugar 
• have kidney or liver disease 
• have a history of gallbladder problems 

A full medical review helps ensure that treatment is safe and appropriate before starting Wegovy.

Does Wegovy have side effects?

Yes. Like all prescription medicines, Wegovy can cause side effects. The most common side effects are related to digestion and usually occur while the body is adjusting to the medication during the early stages of treatment. 

Semaglutide works by affecting appetite and slowing digestion, which is why gastrointestinal symptoms are the most frequently reported side effects. For many people, these symptoms are mild to moderate and improve over time, particularly once the body adjusts to the medication. 

Common side effects may include: 

• nausea 
• vomiting 
• diarrhoea 
• constipation 

These symptoms are most likely to occur during dose increases, which is why Wegovy is introduced gradually through a titration schedule. 

Many people find that side effects can be managed by: 

• eating smaller meals 
• avoiding very fatty or heavy foods 
• staying well hydrated 
• following the prescribed dosing schedule 

Are there any more serious side effects of Wegovy?

Serious side effects from Wegovy are uncommon, but they can occur and require medical attention. Patients should be aware of warning signs and seek medical advice if severe or unusual symptoms develop during treatment. 

The following conditions are rare but potentially serious: 

• Pancreatitis - Intense stomach pain that may radiate to the back.  
• Gallbladder Problems - Gallstones, severe pain, or jaundice.  
• Kidney Issues - Reduced urination or swelling in legs/ankles due to dehydration.  
• Severe Allergic Reactions - Swelling of the face/throat, difficulty breathing, rash, or hives.  
• Vision Changes - Specifically for patients with type 2 diabetes.  

Wegovy mixed with other medications

Wegovy can interact with some medicines, so it is important to tell your clinician about all medications you are taking before starting treatment. This includes prescription medicines, over-the-counter drugs, and supplements. 

Because semaglutide slows stomach emptying, it may affect how quickly some oral medications are absorbed. In most cases, this does not prevent other medicines from working, but your clinician may review your treatment plan to ensure safe use. 

Medicines that may interact with Wegovy include: 

Insulin and some diabetes medicines 
Taking Wegovy with insulin or medicines that increase insulin levels, such as sulfonylureas, may increase the risk of low blood sugar (hypoglycaemia). Your clinician may need to adjust your dose or monitor your blood sugar more closely. 

Certain oral medicines 
Because Wegovy slows stomach emptying, it may change how some oral medicines are absorbed. This can be important for treatments that need consistent levels in the body, such as: 

• Thyroid medicines like levothyroxine 
• Blood thinners such as warfarin 
• Some antibiotics 

Other GLP-1 medications 
Wegovy should not be used alongside other GLP-1 receptor agonists, such as Mounjaro, Ozempic or Saxenda. Using these treatments together can increase the risk of side effects without providing additional benefits. 

If you are unsure whether a medicine you take may interact with Wegovy, speak to your clinician or pharmacist before starting treatment. 

Is Wegovy safe?

Wegovy is considered safe for most people when prescribed and monitored by a qualified healthcare professional. Like any prescription medicine, it must be used according to medical guidance. 

Safety is supported by several factors: 

• Careful eligibility assessment before treatment 
• Gradual dose increases to reduce side effects 
• Regular monitoring during treatment 
• Clear guidance on side effects and warning signs 

However, Wegovy is not suitable for everyone, and treatment should always follow a clinical assessment of medical history and current health conditions. 

What are the benefits of Wegovy other than weight loss?

Wegovy may provide additional health benefits beyond weight loss. Research suggests that semaglutide can improve several obesity-related health markers, including cardiovascular risk factors, blood sugar control, and certain metabolic conditions. 

Many weight-related conditions are closely linked to excess body weight. As weight decreases and appetite regulation improves, some patients may also experience improvements in cardiovascular health, blood sugar regulation, and metabolic function.

Wegovy and heart health

Wegovy is the first weight loss injection shown in clinical trials to reduce the risk of major cardiovascular events in people living with overweight or obesity who already have cardiovascular disease. 

In the large SELECT clinical trial, semaglutide 2.4mg (the active ingredient in Wegovy) was shown to reduce the risk of major cardiovascular events by 20% compared with placebo. These events included heart attack, stroke, and cardiovascular death. 

The study followed more than 17,000 adults with overweight or obesity and established cardiovascular disease who did not have diabetes. Participants taking semaglutide experienced significantly fewer serious heart-related events alongside meaningful weight loss. 

These findings suggest that Wegovy may not only support weight loss, but also help improve long-term heart health in some patients. 

Blood sugar and pressure management

Semaglutide can help improve blood sugar regulation and may also contribute to modest reductions in blood pressure. These effects are particularly relevant for people living with obesity-related metabolic conditions. 

Liver health

Weight loss supported by Wegovy may improve certain markers of liver health in people with obesity-related liver conditions. Excess weight is a major contributor to fatty liver disease, and weight reduction can help improve liver function

Wegovy helps with sleep apnoea

Weight loss achieved with Wegovy may help improve symptoms of obstructive sleep apnoea in some people. Excess body weight is a major risk factor for this condition. 

Storage, administration and disposal

Proper storage, injection technique, and disposal are important for using Wegovy safely and effectively. Patients should follow the instructions provided with the injection pen and any guidance given by their clinician or pharmacist. 

How to store Wegovy

Before use Wegovy should be stored in a refrigerator before use and kept within the recommended temperature range (2-8 degrees Celsius). Storing the medication correctly helps preserve its stability and effectiveness.  

After use, Wegovy can be kept at room temperature for up to 42 days.

Should you keep Wegovy in the refrigerator? 

Yes. Wegovy should be kept in a refrigerator before it is used. This helps maintain the stability of the medication and ensures the injection works as intended. 

Injecting Wegovy

Following the correct injection steps helps ensure Wegovy is delivered safely and effectively. 

1. Wash your hands - start by washing your hands thoroughly with soap and water. This helps reduce the risk of infection when handling the injection pen. 
2. Let it warm - if the pen has been stored in the refrigerator, allow it to reach room temperature before injecting. This can make the injection more comfortable. 
3. Check the pen - check that the pen is not damaged and that the medication inside appears clear and colourless. 
4. Attach a new needle - always attach a new sterile needle before each injection. 
5. Prime your pen - priming helps remove air from the needle and ensures the pen is ready to deliver the dose. 
6. Choose an injection site - common injection areas include the:upper arm, thigh, or abdomen (belly). Rotate injection sites each week to help prevent skin irritation. 
7. Deliver the dose - insert the needle under the skin and press the injection button according to the pen instructions. Hold the pen in place until the dose has been fully delivered. 
8. Finish safely - after the injection, remove the needle and dispose of it safely in a sharps container. 

Missed dose rules

If you miss a Wegovy dose, you should take it as soon as possible within 5 days of the scheduled injection. If more than 5 days have passed, skip the missed dose and take the next injection on your usual weekly day. Do not take 2 doses at the same time to make up for a missed injection. 

The best places to inject

Wegovy should be injected under the skin (subcutaneous injection) in areas with enough fatty tissue. The most common injection sites are the upper arm, thigh, and abdomen. Rotating injection sites each week can help reduce irritation and improve comfort. 

Injecting your upper arm 

The back of the upper arm is one possible injection site for Wegovy. This area may be easier to access with help from another person, as reaching the correct area yourself can be difficult. Always rotate injection sites to avoid repeated injections in the same spot. 

Injecting your thigh 

The front of the thigh is a common and easy injection site for Wegovy. Many people prefer this area because it is simple to reach and allows good control of the injection pen during administration. 

Injecting your belly 

The abdomen (belly) is one of the most frequently used injection sites for Wegovy. Injections should be given at least a few centimetres away from the belly button and rotated around the abdomen to prevent skin irritation. 

What if I inject too much?

If you inject more Wegovy than prescribed, contact a healthcare professional for advice. Taking too much semaglutide may increase the likelihood of side effects such as nausea, vomiting, or digestive discomfort. Seek urgent medical help if severe symptoms develop. 

Injection aftercare

After injecting Wegovy, remove the needle and dispose of it safely. If a small drop of blood appears at the injection site, gentle pressure with a clean tissue is usually enough. Avoid rubbing the area, as this may irritate the skin.

Disposing of your Wegovy pen

Used Wegovy pens and needles should be placed in a sharps container and disposed of according to local pharmacy or healthcare guidance. This helps prevent accidental needle injuries and ensures medical waste is handled safely.

Wegovy diet advice 

Diet plays an important role in achieving the best results with Wegovy. While the medication helps reduce appetite, sustainable weight loss is more likely when it is combined with balanced nutrition and healthy eating habits. 

Most clinicians recommend focusing on regular meals, adequate protein, fibre-rich foods, and portion control. These habits can help support appetite regulation and reduce the likelihood of digestive side effects during treatment. 

[H3] Foods to avoid whilst taking Wegovy 

Very fatty, greasy, or large meals can worsen digestive side effects while taking Wegovy. Some patients find that certain foods increase nausea or stomach discomfort during the early stages of treatment. 

Foods that may trigger symptoms include: 

• deep-fried or high-fat foods 
• very large meals 
• highly processed snack foods 
• foods high in added sugar 

Eating smaller portions and balanced meals can help reduce nausea and support more stable appetite control. 

Wegovy and alcohol 

Alcohol is not strictly prohibited while taking Wegovy, but moderation is recommended. Drinking alcohol can sometimes worsen side effects such as nausea or digestive discomfort. 

Wegovy and fizzy drinks 

Fizzy drinks may increase bloating or stomach discomfort for some people taking Wegovy. Carbonated beverages can contribute to gas and fullness, which may feel more noticeable because the medication slows digestion. If you do want a fizzy drink, we recommend zero-sugar options and moderation. 

Wegovy exercise advice 

Regular physical activity can help improve weight loss outcomes while taking Wegovy. Exercise supports energy balance, cardiovascular health, and long-term weight maintenance. 

Most clinical guidelines recommend combining medication with consistent physical activity and lifestyle changes to support sustainable results. 

How much exercise per week on Wegovy? 

Adults are generally advised to aim for at least 150 minutes of moderate physical activity per week. This level of exercise can support weight management and improve overall health. 

Examples of moderate activity include: 

• brisk walking 
• cycling 
• swimming 
• light jogging 

How much does Wegovy cost in Ireland? 

The cost of Wegovy treatment through myBMI includes a consultation fee and the medication supplied by a partner pharmacy. The consultation covers the clinical assessment required to determine whether the treatment is safe and appropriate for you. 

If you are eligible, your prescription can then be dispensed by a partner pharmacy. The overall cost includes both the medical consultation and the pharmacy treatment cost. 

Wegovy cost table 

Does myBMI offer a prescription or the treatment? 

myBMI provides the clinical consultation and prescription assessment for Wegovy, while the medication itself is supplied by a licensed partner pharmacy. This ensures that treatment is prescribed safely under medical supervision and dispensed through an authorised pharmacy. 

Who is the partner pharmacy 

Wegovy prescriptions issued through myBMI are dispensed by the partner pharmacy, Epharm NI. Once your prescription is approved, the pharmacy prepares and supplies the medication according to pharmacy and prescribing regulations. 

Wegovy overview

Summary of Wegovy Ireland

Wegovy is a clinically proven weekly injection that can help adults in Ireland lose weight by reducing appetite and supporting healthier eating habits. When prescribed through myBMI, treatment is combined with medical oversight, lifestyle guidance, and ongoing support to help people achieve safe, sustainable weight loss.

-Clinical lead, myBMI

Sources

Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen (2026) EMC [accessed 9 March 2026] 

Ozempic 0.25 mg solution for injection in pre-filled pen (2025) EMC [accessed 9 March 2026] 

Non-alcoholic fatty liver disease (NAFLD) (2025) NHS [accessed 9 March 2026] 

Sleep apnoea (2022) NHS [accessed 9 March 2026] 

Physical activity guidelines for adults aged 19 to 64 (2024) NHS [accessed 9 March 2026] 

Semaglutide for managing overweight and obesity (2023) NICE [accessed 9 March 2026] 

Tirzepatide for managing overweight and obesity  (2025) NICE [accessed 9 March 2026] 

Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial (2025) National Library of Medicine [accessed 9 March 2026] 

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (2022) National Library of Medicine [accessed 9 March 2026] 

Wegovy (2025) Novo Nordisk [accessed 9 March 2026]